Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

NCT01039376 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

480

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Leukaemia, Lymphocytic, Chronic

Interventions

BIOLOGICAL: Ofatumumab
OTHER: Observation

Sponsor

Novartis Pharmaceuticals